The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. Factors such as growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination are expected to drive the growth of this market during the forecast period. However, the high cost of enumeration instruments is expected to restrain market growth in the coming years.
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17983056
In 2018, WuXi AppTec opened a Medical Device Testing center in China.
In 2018, Charles River acquired MPI Research, a premier nonclinical contract research organization (CRO).
In 2016, SGS acquired Quality Compliance Laboratories to provide microbiological and analytical testing services to pharmaceutical, nutraceutical, and cosmeceutical industries.